TMCnet News

IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation Of Claims Against CorMedix, Inc. On Behalf Of Investors
[June 30, 2015]

IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation Of Claims Against CorMedix, Inc. On Behalf Of Investors


Goldberg Law PC (www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by CorMedix, Inc. ("CorMedix" or the "Company") (NYSE: CRMD). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.

If you purchased or otherwise acquired CorMedix shares and woul like more information regarding the investigation, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 13650 Marina Pointe Dr. Suite 1404, Marina Del Rey, CA (News - Alert) 90292, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm's website at http://www.Goldberglawpc.com, or by email at [email protected].



CorMedix is a biopharmaceutical company that in-licenses, develops and markets products for the treatment of cardiac, renal, and infectious diseases. On June 29, 2015, SeekingAlpha.com published a report on CorMedix alleging, among other things, that: (1) CorMedix's main product is based on a 1970s-era catheter product acquired for less than $1 million in a bankruptcy sale, apparently after at least two failed sales processes; (2) CorMedix's market size claims are greatly exaggerated; and (3) CorMedix is touting misleading clinical-data, as in-depth industry research shows its Neutrolin/Taurolidine product is a failure and "40% benefit!" versus industry standards is inaccurate. On June 29, 2015, shares of CorMedix fell over 16% as a result of the news.

If you have any questions concerning your legal rights in this case, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at [email protected].


Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


[ Back To TMCnet.com's Homepage ]